

UNITED STATES PATENT AND TRADEMARK OFFICE



M

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/888,079	06/22/2001	Signe Erickson Varner	55821 (71699)	6574
21874 7	590 06/23/2003			
EDWARDS & ANGELL, LLP			EXAMINER	
P.O. BOX 9169 BOSTON, MA 02209		KONTOS, LINA R		
			ART UNIT	PAPER NUMBER
			3763	17
			DATE MAILED: 06/23/2003	10

Please find below and/or attached an Office communication concerning this application or proceeding.

ÉC	
address	
nely. communication.	
the merits is	
	-
i). iner.	
al Stage	
nal application).	

	Application No.	Applicant(s)			
Office Antique Occurrence	09/888,079	VARNER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Lina Kontos	3763			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on	<u> </u>	•			
2a)☐ This action is FINAL . 2b)⊠ Thi	is action is non-final.	•			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4)⊠ Claim(s) <u>23-35</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>23-35</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement. Application Papers					
9)☐ The specification is objected to by the Examine	ſ.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the	e drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).			
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	oved by the Examiner.			
If approved, corrected drawings are required in rep	oly to this Office action.				
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5.	5) Notice of Informal I	y (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/888,079

Art Unit: 3763

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

1.

Claims 23,27,29 are rejected under 35 U.S.C. 102(b) as being anticipated by Adair.

Adair teaches an injection system having a comprising an outer piercing member (10) and an inner cannula (16), longer than the piercing member (Figure 2).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

2.

Claims 24-26,28,30,32-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Peyman in view of Adair.

Peyman teaches a compound for injection in the vitreous portion of the eye wherein the compound is a therapeutic agent consisting of a sterile liquid [0063] containing antibiotics [0064].

Adair, as described above, teaches an injection system comprising a outer piercing member, and an inner cannula.

Application/Control Number: 09/888,079

Art Unit: 3763

It would have been obvious to one skilled in the art at the time of the invention to use the injection method described in Adair to deliver the necessary medicament to the patient's eye.

The gauge size of the cannula depends on the application of the device and the medicament to be delivered.

3.

Claim 31 is rejected under 35 U.S.C. 103(a) as being unpatentable over del Cerro et al. in view of Adair.

Del Cerro et al. teaches an intraretinal delivery and withdrawal device comprising a tip for penetrating the sub-retinal region of the eye. The device can deliver a therapeutic agent or aspirate fluid from the eye (column 4, line 31).

Adair, as described above, teaches an injection system comprising a outer piercing member, and an inner cannula.

It would have been obvious to one skilled in the art at the time of the invention to use the Adair needle formation of the outer needle and inner cannula to perform the injection and aspiration of the del Cerro patent.

Conclusion

4.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

US Patent 6,378,526 B1. teaches a method of opthamalic administration of therapeutic agents.

Application/Control Number: 09/888,079

Art Unit: 3763

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lina Kontos whose telephone number is (703) 306-4207. The examiner can normally be reached on M-F 8:30-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on (703) 308-3552. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9302 for regular communications and (703) 872-9303 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1148.

LRK

June 13, 2003

BRIAN L. CASLER

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700